|
Dec 19
|
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
|
|
Dec 18
|
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
|
|
Dec 14
|
Ionis announces the appointment of Michael Yang to Board of Directors
|
|
Dec 7
|
Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?
|
|
Dec 1
|
Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have earned a 23% return over the last year
|
|
Nov 16
|
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
|
|
Nov 4
|
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2023 Earnings Call Transcript
|
|
Nov 4
|
Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Trading At A 29% Discount?
|
|
Nov 3
|
Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates
|
|
Nov 3
|
Ionis to present at upcoming investor conferences
|
|
Nov 3
|
Q3 2023 Ionis Pharmaceuticals Inc Earnings Call
|
|
Nov 2
|
Ionis Pharmaceuticals Inc (IONS) Reports Q3 2023 Financial Results
|
|
Nov 2
|
Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Nov 2
|
Ionis reports third quarter 2023 financial results
|
|
Sep 12
|
Ionis to host investor and analyst day event
|
|
Sep 8
|
Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?
|
|
May 24
|
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
|